tabimorelin
Small moleculeexperimental
Clinical trial activity
0 trials · 0 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Mechanism of action
- Ghrelin receptorAGONIST
GHSR agonist
Ghrelin mimetic. Discontinued lack of efficacy and possible side effects due to CYP3A4 inhibition.
- Cytochrome P450 3A4INHIBITOR
CYP3A4 inhibitor
Ghrelin mimetic. Discontinued lack of efficacy and possible side effects due to CYP3A4 inhibition.
Chemistry & pharmacology
Loading structure…
SMILES
CNC(=O)[C@@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1ccc2ccccc2c1)N(C)C(=O)/C=C/CC(C)(C)N- Mol. weight
- 528.7 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL281764 ↗
Also known as
- nn 703
- nn-703
- nn-703
- nn-703
- tabimorelin
- tabimorelin
- tabimorelin